Related Experiment Video
Updated: Aug 15, 2026

Efficient Differentiation of Mouse Embryonic Stem Cells into Motor Neurons
Published on: June 9, 2012
Endomorphin-1: induction of motor behavior and lack of receptor desensitization
1Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles, California 90095, USA.
Abstract:
The endomorphins are recently discovered endogenous agonists for the mu-opioid receptor (Zadina et al., 1997). Endomorphins produce analgesia; however, their role in other brain functions has not been elucidated. We have investigated the behavioral effects of endomorphin-1 in the globus pallidus, a brain region that is rich in mu-opioid receptors and involved in motor control. Bilateral administration of endomorphin-1 in the globus pallidus of rats induced orofacial dyskinesia. This effect was dose-dependent and at the highest dose tested (18 pmol per side) was sustained during the 60 min of observation, indicating that endomorphin-1 does not induce rapid desensitization of this motor response. In agreement with a lack of desensitization of mu-opioid receptors, 3 hr of continuous exposure of the cloned mu receptor to endomorphin-1 did not diminish the subsequent ability of the agonist to inhibit adenylate cyclase activity in cells expressing the cloned mu-opioid receptor. Confirming the involvement of mu-opioid receptors, the behavioral effect of endomorphin-1 in the globus pallidus was blocked by the opioid antagonist naloxone and the mu-selective peptide antagonist Cys(2)-Tyr(3)-Orn(5)-Pen(7) amide (CTOP). Furthermore, the selective mu receptor agonist [d-Ala(2)-N-Me-Phe(4)-Glycol(5)]-enkephalin (DAMGO) also stimulated orofacial dyskinesia when infused into the globus pallidus, albeit transiently. Our findings suggest that endogenous mu agonists may play a role in hyperkinetic movement disorders by inducing sustained activation of pallidal opioid receptors.
Insights
Endomorphin-1, a mu-opioid receptor agonist, induces sustained orofacial dyskinesia when administered to the rat globus pallidus, suggesting a role in hyperkinetic movement disorders.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Endomorphins are novel endogenous agonists for mu-opioid receptors.
- Their functions beyond analgesia, particularly in motor control, remain largely unknown.
- The globus pallidus is rich in mu-opioid receptors and implicated in motor regulation.
Purpose of the Study:
- To investigate the behavioral effects of endomorphin-1 in the globus pallidus.
- To determine the role of pallidal mu-opioid receptors in motor control.
- To explore the potential involvement of endomorphins in hyperkinetic movement disorders.
Main Methods:
- Bilateral administration of endomorphin-1 into the globus pallidus of rats.
- Dose-response and time-course analysis of induced behaviors.
- Assessment of mu-opioid receptor desensitization in vitro.
- Pharmacological blockade using naloxone and CTOP.
- Infusion of a selective mu-opioid agonist (DAMGO).
Main Results:
- Endomorphin-1 induced dose-dependent orofacial dyskinesia in rats.
- The motor effect was sustained for 60 minutes, indicating no rapid desensitization.
- Endomorphin-1 did not desensitize mu-opioid receptors' ability to inhibit adenylate cyclase.
- The effects were blocked by naloxone and CTOP, confirming mu-opioid receptor involvement.
- DAMGO also induced transient orofacial dyskinesia.
Conclusions:
- Endogenous mu-opioid agonists, like endomorphin-1, can induce motor disturbances.
- Sustained activation of pallidal opioid receptors may contribute to hyperkinetic movement disorders.
- Endomorphins represent a potential target for understanding and treating movement abnormalities.

